Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.
作者信息
Starace Michela, Cedirian Stephano, Rapparini Luca, Pileri Alessandro, Carrera Cristina, Giavedoni Priscila, Alonso de Leon M Teresa, Kraehenbuehl Lukas, Elshot Yannick S, Apalla Zoe, Papegeorgiou Chryssoula, Nikolaou Vasiliki, Radevic Tatjana, Lengyel Zsuzsanna, Sollena Pietro, Peris Ketty, Rossi Ernesto, Fattore Davide, Koumaki Dimitra, Boada Aram, Forsea Ana-Maria, Segura Sonia, Freites-Martinez Azael, Riganti Julia, Avitan-Hersh Emily, Saffuri Nada, Peuvrel Lucie, Dezoteux Frédéric, Piraccini Bianca Maria, Sibaud Vincent
机构信息
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
出版信息
JAMA Dermatol. 2025 Feb 1;161(2):216-218. doi: 10.1001/jamadermatol.2024.5136.
Abstract
摘要
相似文献
1
Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.免疫检查点抑制剂诱导的白癜风样色素脱失。
JAMA Dermatol. 2025 Feb 1;161(2):216-218. doi: 10.1001/jamadermatol.2024.5136.
2
Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.病例报告：非黑色素瘤晚期癌症中与免疫检查点抑制剂相关的白癜风样色素脱失：三例报告及个体患者数据汇总分析
Front Oncol. 2023 Jan 13;12:1099108. doi: 10.3389/fonc.2022.1099108. eCollection 2022.
3
Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management.免疫检查点抑制剂诱导的癌症患者白癜风：特征与管理。
Arch Dermatol Res. 2023 Aug;315(6):1697-1703. doi: 10.1007/s00403-023-02577-7. Epub 2023 Feb 21.
4
Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals.可切除III期黑色素瘤患者辅助性检查点抑制剂治疗继发的白癜风样色素减退：来自两家三级医院的队列研究
Melanoma Res. 2025 Apr 1;35(2):148-152. doi: 10.1097/CMR.0000000000001018. Epub 2025 Jan 7.
5
Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.非小细胞肺癌患者接受帕博利珠单抗治疗后出现白癜风样色素脱失：一例报告
Transl Lung Cancer Res. 2020 Aug;9(4):1585-1590. doi: 10.21037/tlcr-20-386.
6
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.免疫检查点抑制剂诱导的癌症患者白癜风的发生和结局：一项回顾性队列研究。
Drug Saf. 2020 Feb;43(2):111-117. doi: 10.1007/s40264-019-00875-6.
7
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.免疫检查点抑制剂引起的皮肤毒性的临床相关性和分类：来自欧洲皮肤病学会和皮肤病学癌症患者工作组的一项多中心研究。
Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6.
8
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.黑色素瘤患者的免疫检查点抑制剂诱导的白癜风：专家意见。
Expert Opin Drug Saf. 2021 Aug;20(8):883-888. doi: 10.1080/14740338.2021.1915279. Epub 2021 Apr 27.
9
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.免疫检查点抑制剂癌症治疗在患有 1 型糖尿病患者中的安全性和疗效。
Front Endocrinol (Lausanne). 2023 Oct 31;14:1242830. doi: 10.3389/fendo.2023.1242830. eCollection 2023.
10
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.白癜风样白化病作为晚期黑色素瘤患者对免疫检查点抑制剂临床反应的指标。
J Cancer Res Clin Oncol. 2022 Sep;148(9):2529-2538. doi: 10.1007/s00432-021-03811-3. Epub 2021 Sep 30.
引用本文的文献
1
Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database.药物性白癜风：基于FAERS数据库的真实世界药物警戒分析
PLoS One. 2025 Sep 8;20(9):e0332079. doi: 10.1371/journal.pone.0332079. eCollection 2025.
本文引用的文献
1
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.皮肤免疫相关不良反应与接受免疫检查点抑制剂治疗的晚期癌症患者的总生存期延长相关：一项多机构队列研究。
J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048. Epub 2023 Feb 2.
2
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.免疫检查点抑制剂相关皮肤毒性：一项观察性、药物警戒研究。
J Invest Dermatol. 2022 Nov;142(11):2896-2908.e4. doi: 10.1016/j.jid.2022.04.020. Epub 2022 May 20.
3
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.抗程序性细胞死亡蛋白 1 和抗程序性细胞死亡配体 1 治疗的患者中皮肤免疫相关不良事件与生存改善相关。
JAMA Dermatol. 2022 Feb 1;158(2):189-193. doi: 10.1001/jamadermatol.2021.5476.
4
European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.欧洲免疫检查点抑制剂相关皮肤不良反应管理建议。EADV 工作组“癌症患者皮肤病学”立场声明。
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):332-350. doi: 10.1111/jdv.17855. Epub 2021 Dec 15.
5
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.免疫检查点抑制剂治疗患者皮肤毒性的发生的流行病学和危险因素：美国人群水平分析。
J Am Acad Dermatol. 2022 Mar;86(3):563-572. doi: 10.1016/j.jaad.2021.03.094. Epub 2021 Apr 2.
6
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.白癜风与帕博利珠单抗治疗转移性黑色素瘤患者肿瘤应答的关联。
JAMA Dermatol. 2016 Jan;152(1):45-51. doi: 10.1001/jamadermatol.2015.2707.
Zotero 插件